论文部分内容阅读
目的:探讨达格列净对2型糖尿病患者的动脉内膜中层厚度(intima-media thickness,IMT)的影响.方法:113例2型糖尿病患者随机分为达格列净组(58例)和对照组(55例),均在生活方式干预的同时口服阿司匹林0.1 g/d及阿托伐他汀20 mg/d.达格列净组在上述治疗基础上每天服用达格列净10 mg,对照组加用其他类口服降糖药和(或)胰岛素治疗,总疗程24周,对2组患者分别进行各项生化指标及IMT的检测及比较.结果:与治疗前相比,达格列净组治疗后IMT明显下降(P＜0.01),对照组治疗前、后的IMT差异无统计学意义(P＞0.05).治疗后2组间颈动脉IMT比较,差异有统计学意义(P＜0.01),而2组之间血糖及血压下降程度比较差异无统计学意义(P＞0.05).结论:达格列净能够降低2型糖尿病患者的IMT,考虑该药治疗2型糖尿病患者有一定的心血管获益与此有关.“,”AIM:To assess the effects of dapagliflozin on intima-medial thickness (IMT) of carotid artery in type 2 diabetic mellitus patients.METHODS:A total of 113 patients of type 2 diabetic mellitus were divided into dapagliflozin group (58 cases) and control group (55 cases).All patients were recruited in this randomized trial.Based on the intervention of life style, all patients undertook oral aspirin 0.1 g/d and atorvastatin 20 mg/d.The dapagliflozin group was given dapagliflozin 10 mg every day, while the control group was given other oral antidiabetic drug with/without insulin therapy.Course of treatment was 24 weeks.The various biochemical indices and carotid artery IMT were detected and the data were analyzed and compared between the two groups.RESULTS:In the dapagliflozin group, the IMT decreased after dapagliflozin therapy (P ＜0.01).In the control group, the distinction of IMT had not statistical significant between before and after therapy (P＞ 0.05).There were significant differences in carotid artery IMT between the two groups after therapy (P ＜ 0.01), while there was no statistically significant difference between decreased blood sugar and blood pressure level (P＞ 0.05).CONCLUSION:Dapagliflozin can decrease the IMT in patients with type 2 diabetic mellitus, which is closely related to cardiovascular benefit in patients with type 2 diabetic mellitus.